Holen Sie sich die Stockscreener-App
538.44
1.09%
5.62
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt UTHR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$532.82
Offen:
$533.83
24-Stunden-Volumen:
368.51K
Relative Volume:
0.85
Marktkapitalisierung:
$23.61B
Einnahmen:
$3.13B
Nettoeinkommen (Verlust:
$1.27B
KGV:
20.41
EPS:
26.3851
Netto-Cashflow:
$1.12B
1W Leistung:
+12.65%
1M Leistung:
+13.72%
6M Leistung:
+32.99%
1J Leistung:
+76.38%
1-Tages-Spanne:
$533.83
$543.37
1-Wochen-Bereich:
$495.50
$548.12
52-Wochen-Spanne:
$266.98
$548.12
United Therapeutics Corp Stock (UTHR) Company Profile
Firmenname
United Therapeutics Corp
Sektor
Telefon
(301) 608-9292
Adresse
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, ZTS, HLN, TEVA
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
538.71 | 23.35B | 3.13B | 1.27B | 1.12B | 26.39 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.75 | 56.14B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.50 | 48.74B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.05 | 44.85B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.52 | 34.12B | 17.41B | 1.43B | 1.00B | 1.2182 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Eingeleitet | Wells Fargo | Underweight |
| 2025-09-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | Hochstufung | Goldman | Sell → Neutral |
| 2024-02-05 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-06 | Eingeleitet | UBS | Buy |
| 2022-12-05 | Eingeleitet | Goldman | Sell |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-20 | Bestätigt | BofA Securities | Underperform |
| 2022-09-19 | Fortgesetzt | Wedbush | Outperform |
| 2022-02-11 | Eingeleitet | BTIG Research | Neutral |
| 2021-07-14 | Hochstufung | Argus | Hold → Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-01 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-25 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-03-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-27 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-01-31 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-03 | Eingeleitet | BofA/Merrill | Underperform |
| 2019-08-01 | Hochstufung | Jefferies | Underperform → Hold |
| 2019-08-01 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | Hochstufung | UBS | Sell → Neutral |
| 2019-05-09 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | Hochstufung | Standpoint Research | Hold → Buy |
| 2018-08-08 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | Bestätigt | Barclays | Underweight |
| 2018-01-18 | Fortgesetzt | Credit Suisse | Underperform |
| 2017-12-27 | Bestätigt | Wedbush | Outperform |
| 2017-04-27 | Bestätigt | Wedbush | Outperform |
| 2017-03-30 | Eingeleitet | UBS | Sell |
| 2017-03-16 | Eingeleitet | Credit Suisse | Underperform |
Alle ansehen
United Therapeutics Corp Aktie (UTHR) Neueste Nachrichten
United Therapeutics Stock Surges 32% in 6 Months: Here's Why - TradingView
UBS raises United Therapeutics stock price target to $705 on catalysts - Investing.com Nigeria
Cantor Fitzgerald raises United Therapeutics stock price target to $625 - Investing.com Nigeria
Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock - MarketBeat
Inhaled IPF drug from United Therapeutics slows lung scarring in trial - Stock Titan
United Therapeutics: Ralinepag Is The Ultimate Defense Against Yutrepia (Rating Upgrade) - Seeking Alpha
Capital Fund Management S.A. Purchases 20,410 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
United Therapeutics Corp (UTHR) Shares Up 3.04% on Mar 10 - GuruFocus
United Therapeutics (NASDAQ:UTHR) Sets New 1-Year HighHere's What Happened - MarketBeat
United Therapeutics stock hits all-time high at 537.83 USD - Investing.com
United Therapeutics (UTHR) Surges 10.7%: Is This an Indication of Further Gains? - Yahoo Finance
Grantham Mayo Van Otterloo & Co. LLC Acquires 6,079 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Insider Sell: Judy Olian Sells 200 Shares of United Therapeutics Corp (UTHR) - GuruFocus
United Therapeutics Corp (UTHR) Shares Up 8.91% on Mar 9 - GuruFocus
United Therapeutics Launches $1.5 Billion Accelerated Share Repurchases With Citi Under $2 Billion Buyback - TradingView
United Therapeutics stock jumps 9% on $2B buyback program - Investing.com
United Therapeutics stock buyback signals franchise confidence, TD Cowen says - Investing.com Nigeria
United Therapeutics (NASDAQ:UTHR) Shares Gap UpStill a Buy? - MarketBeat
United Therapeutics authorizes $2 billion buyback program - Investing.com
United Therapeutics sends $1.5B upfront for stock, $500M left - Stock Titan
First Trust Advisors LP Trims Stake in United Therapeutics Corporation $UTHR - MarketBeat
Rhenman & Partners Asset Management AB Buys Shares of 8,000 United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Shares Positive Study Results for its Bioengineered Liver - Medical Product Outsourcing
Ray Kurzweil Sells 4,910 Shares of United Therapeutics Corp - GuruFocus
United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares - MarketBeat
United Therapeutics (NASDAQ:UTHR) Director Sells $978,840.00 in Stock - MarketBeat
United Therapeutics (UTHR) Receives Increased Price Target from UBS | UTHR Stock News - GuruFocus
Fisher Asset Management LLC Buys 4,987 Shares of United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corp (NASDAQ:UTHR) Emerges as a Peter Lynch-Style GARP Candidate - ChartMill
United Therapeutics Shares Drop 1.69% as Revenue Shortfall Outweighs Profit Surpass; Trading Volume Places 493rd - Bitget
AustralianSuper Pty Ltd Cuts Stake in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics pill shows late-stage success in rare lung disease PAH - IndiaMedToday
TD Cowen reiterates United Therapeutics stock Buy on ralinepag trial success - Investing.com India
Insider Sell: Jan Malcolm Sells Shares of United Therapeutics Co - GuruFocus
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells 9,500 Shares - TradingView
United Therapeutics CEO to give update at Leerink healthcare conference - Stock Titan
Leerink raises United Therapeutics stock price target on trial data - Investing.com South Africa
Leerink raises United Therapeutics stock price target on trial data By Investing.com - Investing.com India
Jefferies raises United Therapeutics stock price target on trial data By Investing.com - Investing.com Australia
Jefferies raises United Therapeutics stock price target on trial data - Investing.com South Africa
Insider Sell: Judy Olian Sells Shares of United Therapeutics Cor - GuruFocus
United Therapeutics Hits Day High with 13% Surge in Strong Intraday Performance - Markets Mojo
H.C. Wainwright reiterates Buy on United Therapeutics stock - Investing.com South Africa
H.C. Wainwright reiterates Buy on United Therapeutics stock By Investing.com - Investing.com UK
United Therapeutics (UTHR): Investor Outlook With A 13% Upside Potential - DirectorsTalk Interviews
United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy - marketscreener.com
United Therapeutics' Trial Shows 55% Drop in Lung Disease Worsening - Benzinga
United Therapeutics reports positive phase 3 trial for ralinepag By Investing.com - Investing.com Canada
United Therapeutics (UTHR) Reports Positive Phase 3 Results for Ralinepag - GuruFocus
United Therapeutics reports positive phase 3 trial for ralinepag - Investing.com
Finanzdaten der United Therapeutics Corp-Aktie (UTHR)
Umsatz
Nettogewinn
Free Cashflow
ENV
United Therapeutics Corp-Aktie (UTHR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | Chairperson & CEO |
Mar 11 '26 |
Sale |
539.54 |
9,500 |
5,125,647 |
130 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Mar 10 '26 |
Option Exercise |
146.03 |
9,500 |
1,387,285 |
9,630 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Mar 10 '26 |
Sale |
539.71 |
9,500 |
5,127,273 |
130 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Mar 09 '26 |
Option Exercise |
146.03 |
9,500 |
1,387,285 |
9,630 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Mar 09 '26 |
Sale |
518.03 |
9,500 |
4,921,275 |
130 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Mar 06 '26 |
Option Exercise |
146.03 |
9,500 |
1,387,285 |
9,630 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Mar 06 '26 |
Sale |
477.67 |
9,500 |
4,537,853 |
130 |
| Olian Judy D. | Director |
Mar 06 '26 |
Sale |
510.00 |
200 |
102,000 |
4,645 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Mar 05 '26 |
Option Exercise |
146.03 |
9,500 |
1,387,285 |
9,630 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Mar 05 '26 |
Sale |
484.55 |
9,500 |
4,603,232 |
130 |
0.90%
2.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):